Wells Fargo & Company Protalix Bio Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $507 Billion
- Q3 2025
A detailed history of Wells Fargo & Company transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 42,831 shares of PLX stock, worth $79,665. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,831
Previous 36,034
18.86%
Holding current value
$79,665
Previous $53,000
79.25%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PLX
# of Institutions
82Shares Held
10.6MCall Options Held
23.6KPut Options Held
95.4K-
Opaleye Management Inc. Boston, MA2.58MShares$4.8 Million0.96% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.32MShares$2.45 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL902KShares$1.68 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA820KShares$1.52 Million0.0% of portfolio
-
Stratos Wealth Partners, Ltd.500KShares$930,0000.01% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $92.5M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...